Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats

BACKGROUND: Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Skarbaliene, Jolanta, Mathiesen, Jesper Mosolff, Larsen, Bjarne Due, Thorkildsen, Christian, Petersen, Yvette Miata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029296/
https://www.ncbi.nlm.nih.gov/pubmed/36944922
http://dx.doi.org/10.1186/s12876-023-02716-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029296/
https://www.ncbi.nlm.nih.gov/pubmed/36944922
http://dx.doi.org/10.1186/s12876-023-02716-4

Ejemplares similares